Under two projects, which began at the end of 2004, Cenix has been validating candidate genes for drug targets provided by Schering using high-throughput RNAi and high-content phenotype analyses in human and mouse cell lines.
The companies disclosed neither the disease areas nor financial terms of the agreement.